PHR:NYE-Phreesia Inc (USD)

COMMON STOCK | Health Information Services |

Last Closing

USD 27.28

Change

+0.06 (+0.22)%

Market Cap

N/A

Volume

0.32M

Analyst Target

USD 30.11
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-23 )

Largest Industry Peers for Health Information Services

Symbol Name Price(Change) Market Cap
SOLV Solventum Corp.

-0.06 (-0.08%)

USD 10.78B
DOCS Doximity Inc

-0.36 (-0.64%)

USD 9.97B
WEAV Weave Communications Inc

+0.15 (+0.95%)

USD 1.13B
MPLN MultiPlan Corporation

-0.18 (-1.13%)

USD 0.23B
AMWL American Well Corp

+0.68 (+6.61%)

USD 0.11B
OWLT Owlet Inc

-0.01 (-0.22%)

USD 0.07B
TDOC Teladoc Inc

+0.26 (+2.63%)

N/A
FOXO FOXO Technologies Inc.

N/A

N/A
EVH Evolent Health Inc

+0.18 (+1.80%)

N/A
VEEV Veeva Systems Inc Class A

-6.10 (-2.66%)

N/A

ETFs Containing PHR

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health Information Services) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 8.43% 73% C 87% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 8.43% 73% C 87% B+
Trailing 12 Months  
Capital Gain 8.90% 80% B- 56% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 8.90% 80% B- 47% F
Trailing 5 Years  
Capital Gain -9.04% 50% F 39% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -9.04% 50% F 21% F
Average Annual (5 Year Horizon)  
Capital Gain 9.92% 70% C- 64% D
Dividend Return 9.92% 70% C- 59% D-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 65.72% 60% D- 14% F
Risk Adjusted Return 15.09% 80% B- 31% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector